Expert Opinion on Therapeutic Patents, Год журнала: 2025, Номер unknown
Опубликована: Апрель 22, 2025
The Angiotensin-converting enzyme 2 (ACE2) receptor, crucial for coronavirus recognition of host cells, is a key target therapeutic intervention against SARS-CoV-2 and related coronaviruses. Therefore, thoroughly investigating the interaction mechanism between ACE2 Spike protein (S protein), as well developing targeted inhibitors based on this mechanism, vital effectively controlling spread preventing potential future pandemics caused by other This article comprehensively reviews mechanisms underlying ACE2-S that facilitates entry into cells. It also analyzes patent landscape regarding targeting interface since 2019. In five years outbreak SARS-CoV-2, numerous methods design strategies have been employed to develop innovative therapeutics Among these approaches, both receptor S gained significant interest due their in blocking various Despite facing challenges similar protein-protein inhibitors, progress has made through virtual screening, covalent binding, peptide modification strategies. However, obstacles persist clinical translation, necessitating multidisciplinary strategy integrates state-of-the-art methodologies optimize S-ACE2 interface-targeted drug discovery.
Язык: Английский